

## Sai Life Sciences IPO

**Sai Life Sciences IPO Price:** ₹522 to ₹549 per share  
**IPO Dates:** 11 December 2024 - 13 December 2024

### Company Overview



# Sai

Sai Life Sciences Limited, established in January 1999 as 'Sai Dru Syn Laboratories Ltd,' has undergone several name changes over the years, ultimately adopting its current name in May 2012. The company operates as a fully integrated, innovator-focused contract research, development, and manufacturing organization (CRDMO). It provides comprehensive services across the drug discovery, development, and manufacturing value chain for small-molecule new chemical entities (NCEs).

### Key Milestones in Corporate Evolution

- **1999:** Incorporated as Sai Dru Syn Laboratories Ltd in Hyderabad, Telangana.
- **2003:** Renamed as Sai Life Sciences Ltd.
- **2006:** Rebranded to Sai Advantium Pharma Ltd.
- **2012:** Final name change back to Sai Life Sciences Ltd.

### Core Services and Capabilities

Sai Life Sciences serves global pharmaceutical innovators and biotechnology firms, offering:

1. **Contract Research Organization (CRO) Services:** Integrated discovery capabilities in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK).
2. **Contract Development and Manufacturing Organization (CDMO) Services:** Chemistry, manufacturing, and control (CMC) capabilities with a mix of commercial and under-development molecules.

The company's infrastructure includes research laboratories in Watertown (Greater Boston, MA) and Manchester, UK, along with cost-efficient manufacturing facilities in India.

## Clientele and Market Presence

Sai Life Sciences has cemented its reputation as a reliable partner for pharmaceutical and biotechnology innovators. During the Financial Year 2024, the company served over 280 pharmaceutical innovators and 230 biotechnology firms. Notably, it collaborated with 18 of the top 25 global pharmaceutical companies based on 2023 revenues. Its operations extend across regulated markets such as the United States, the United Kingdom, Europe, and Japan, showcasing its global reach and compliance with stringent industry standards.

## Workforce and Expertise

As of September 30, 2024, Sai Life Sciences employed 3,135 individuals, including 2,353 scientific staff with advanced qualifications. This includes 302 Ph.D. holders and 1,475 professionals with master's degrees, underscoring the company's commitment to expertise-driven innovation. The business development team, comprising 16 seasoned professionals, is strategically located worldwide, with six members in the United States, nine in the United Kingdom and Europe, and one in Japan, ensuring close collaboration with clients in key markets.

## Competitive Strengths

Sai Life Sciences differentiates itself through:

1. **Integrated CRDMO Platform:** Acting as a one-stop solution for discovery, development, and manufacturing.
2. **Advanced R&D Infrastructure:** Modern facilities and a robust regulatory compliance track record.
3. **Customer Relationships:** Strong and long-standing relationships with a diverse client base.
4. **Talent Pool and Leadership:** A skilled management team and a highly qualified scientific workforce.
5. **Global Reach:** Strategic presence near innovation hubs complemented by cost-effective Indian facilities.
6. **Growth and Profitability:** Strategic investments contributing to improved profitability metrics.

Sai Life Sciences is among the largest integrated CRDMOs in India, showcasing a balanced mix of commercial and under-development projects, and positioning itself as a leader in pharmaceutical innovation and manufacturing.

## Sai Life Sciences IPO Specifics:

IPO Date	December 11, 2024 to December 13, 2024
Listing Date	Wednesday, December 18, 2024
Face Value	₹1 per share
Price Band	₹522 to ₹549 per share
Lot Size	27 Shares
Total Issue Size	55,421,123 shares (aggregating up to ₹3,042.62 Cr)
Fresh Issue	17,304,189 shares (aggregating up to ₹950.00 Cr)
Offer For Sale	38,116,934 shares (aggregating up to ₹2,092.62 Cr)
Issue Type	Book Built Issue IPO
Listing At	BSE, NSE
Share holding pre issue	190,685,340
Share holding post issue	207,989,529

## Sai Life Sciences IPO Timetable (Important Dates)

IPO Open Date	Wednesday, December 11, 2024
IPO Close Date	Friday, December 13, 2024
Basis of Allotment	Monday, December 16, 2024
Initiation of Refunds	Tuesday, December 17, 2024
Credit of Shares to Demat	Tuesday, December 17, 2024
Listing Date	Wednesday, December 18, 2024
Cut-off time for UPI mandate confirmation	5 PM on December 13, 2024

## Sai Life Sciences IPO Lot Size

Bidders have the opportunity to bid for a minimum of 27 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.

Application	Lots	Shares	Amount
Retail (Min)	1	27	₹14,823
Retail (Max)	13	351	₹1,92,699
S-HNI (Min)	14	378	₹2,07,522
S-HNI (Max)	67	1,809	₹9,93,141
B-HNI (Min)	68	1,836	₹10,07,964

## Sai Life Sciences IPO Reservation

QIB Shares Offered	Not more than 50% of the Net offer
Retail Shares Offered	Not less than 35% of the Offer
NII (HNI) Shares Offered	Not less than 15% of the Offer

## Don't Miss Out!

Whether you're a seasoned investor or just starting out, Lakshmishree ensures you don't miss out on premier IPO opportunities. Dive into the future of investing with Lakshmishree.

**APPLY NOW**

## Sai Life Sciences Limited IPO Financial Information

Sai Life Sciences Limited saw a 20% growth in its revenue and a substantial 729% surge in profit after tax (PAT) from the fiscal year ending on March 31, 2023, to March 31, 2024.

Period Ended	31 Mar 2022	31 Mar 2023	31 Mar 2024	30 Sept 2024
Assets	2164.23	2186.65	2275.14	2476.78
Revenue	897.74	897.74	1494.27	693.35
Profit After Tax	6.23	6.23	82.81	28.01
Net Worth	877.76	877.76	974.34	1044.75
Reserves and Surplus	859.17	859.17	953.99	1025.44
Total Borrowing	751.32	751.32	710.16	764.49

Amount in ₹ Crore

## Key Performance Indicator - Sai Life Sciences IPO

KPI	Values
Market Cap.	₹ 11,418.63 Cr
EPS	₹4.34
P/E (x)	126.42
ROE	11.79%
ROCE	15.96%
RoNW	8.13%
P/BV	10.18

as of Mar 31, 2024

## Objects of the Issue:

The company intends to utilize the Net Proceeds for the following purposes:

1. Repayment or prepayment of certain outstanding borrowings, either in full or in part.
2. General corporate purposes.

## Prospectus Links:

**Prospectus:** Official documents that provide detailed information about the IPO and the company.

[Sai Life Sciences Limited IPO DRHP.](#)

[Sai Life Sciences Limited IPO RHP](#)